BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31102143)

  • 1. Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
    Ouwens MJNM; Mukhopadhyay P; Zhang Y; Huang M; Latimer N; Briggs A
    Pharmacoeconomics; 2019 Sep; 37(9):1129-1138. PubMed ID: 31102143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.
    Chaudhary MA; Edmondson-Jones M; Baio G; Mackay E; Penrod JR; Sharpe DJ; Yates G; Rafiq S; Johannesen K; Siddiqui MK; Vanderpuye-Orgle J; Briggs A
    Med Decis Making; 2023 Jan; 43(1):91-109. PubMed ID: 36259353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
    Federico Paly V; Kurt M; Zhang L; Butler MO; Michielin O; Amadi A; Hernlund E; Johnson HM; Kotapati S; Moshyk A; Borrill J
    MDM Policy Pract; 2022; 7(1):23814683221089659. PubMed ID: 35356551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.
    Bullement A; Willis A; Amin A; Schlichting M; Hatswell AJ; Bharmal M
    BMC Med Res Methodol; 2020 May; 20(1):103. PubMed ID: 32375680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
    Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
    J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma.
    Klijn SL; Fenwick E; Kroep S; Johannesen K; Malcolm B; Kurt M; Kiff C; Borrill J
    Pharmacoeconomics; 2021 Mar; 39(3):345-356. PubMed ID: 33428174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges with Estimating Long-Term Overall Survival in Extensive Stage Small-Cell Lung Cancer: A Validation-Based Case Study.
    Johal S; Brannman L; Genestier V; Cawston H
    Clinicoecon Outcomes Res; 2024; 16():97-109. PubMed ID: 38433888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
    Lanitis T; Proskorovsky I; Ambavane A; Hunger M; Zheng Y; Bharmal M; Phatak H
    Adv Ther; 2019 Sep; 36(9):2327-2341. PubMed ID: 31350728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies.
    Monnickendam G
    Value Health; 2024 Feb; ():. PubMed ID: 38428815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study.
    Bullement A; Latimer NR; Bell Gorrod H
    Value Health; 2019 Mar; 22(3):276-283. PubMed ID: 30832965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrapolating Parametric Survival Models in Health Technology Assessment: A Simulation Study.
    Gallacher D; Kimani P; Stallard N
    Med Decis Making; 2021 Jan; 41(1):37-50. PubMed ID: 33283635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
    Gray J; Sullivan T; Latimer NR; Salter A; Sorich MJ; Ward RL; Karnon J
    Med Decis Making; 2021 Feb; 41(2):179-193. PubMed ID: 33349137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1.
    Vadgama S; Mann J; Bashir Z; Spooner C; Collins GP; Bullement A
    Value Health; 2022 Jun; 25(6):1010-1017. PubMed ID: 35667774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
    Galli G; De Toma A; Pagani F; Randon G; Trevisan B; Prelaj A; Ferrara R; Proto C; Signorelli D; Ganzinelli M; Zilembo N; de Braud F; Garassino MC; Lo Russo G
    Lung Cancer; 2019 Nov; 137():38-42. PubMed ID: 31526910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.
    Grant TS; Burns D; Kiff C; Lee D
    Pharmacoeconomics; 2020 Apr; 38(4):385-395. PubMed ID: 31848900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
    Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
    BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival.
    Lee S; Lambert PC; Sweeting MJ; Latimer NR; Rutherford MJ
    Value Health; 2024 Jan; 27(1):51-60. PubMed ID: 37858887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities.
    Grumberg V; Roze S; Chevalier J; Borrill J; Gaudin AF; Branchoux S
    Int J Technol Assess Health Care; 2022 Mar; 38(1):e28. PubMed ID: 35331347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
    Sweeting MJ; Rutherford MJ; Jackson D; Lee S; Latimer NR; Hettle R; Lambert PC
    Med Decis Making; 2023 Aug; 43(6):737-748. PubMed ID: 37448102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.